JAZZ News and Press, Jazz Pharmaceuticals plc From 06/07/22

Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting PR Newswire Oral presentation confirms pati...

The Cannabis Sector And Top Marijuana Stocks In June Top marijuana stocks have started June with some momentum after reaching new lows in May. Many experts are calling this recent rise a bear market rally since the broader markets have regained some of their losses from last month. ...

Top Marijuana Stocks To Watch As New Month Of Trading Begins At the moment marijuana stocks are still in a volatile place. Over the last several weeks many cannabis stocks have quickly risen and fallen. Yet this is not all bad if you are able to play the short game better than o...

Jazz Pharmaceuticals to Participate in the Jefferies Healthcare Conference PR Newswire DUBLIN , June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Jefferies Healthcare Conference o...

Jazz Pharmaceuticals to Present New Data at SLEEP 2022 Reinforcing Leadership in Sleep Medicine PR Newswire Seventeen abstracts debut new data across narcolepsy and idiopathic hypersomnia DUBLIN , June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals ...

A delay in approval of Avadel Pharmaceuticals (NASDAQ:AVDL) FT218 for daytime sleepiness and cataplexy is seen as a boon for rival Jazz Pharmaceuticals (NASDAQ:JAZZ). The delay, due to a REMS patent, is an "incremental positive" for Jazz Pharmaceuticals, said Goldman Sachs analyst Madhu Kumar...

Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis, Alzheimer’s, Parkinson’s, among others. Accordin...

Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA Meetings PR Newswire Key data includes ASCO oral presentation of data from the Rylaze ® (asparaginase erwinia chrysanthemi (recombinant)-rywn) ...

Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea PR Newswire Axsome is committed to providing patients uninterrupted access to Sunosi and advancing resea...

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with their 2022 Q1 earnings call. For further details see: Jazz Pharmaceuticals plc 2022 Q1 - Results - Earnings Call Presentation